These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 18336132

  • 1. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
    Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I.
    Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
    [Abstract] [Full Text] [Related]

  • 2. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Ferrari P, Marti HP, Pfister M, Frey FJ.
    J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
    [Abstract] [Full Text] [Related]

  • 3. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 4. The value of irbesartan in the management of hypertension.
    Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C.
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [Abstract] [Full Text] [Related]

  • 6. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [Abstract] [Full Text] [Related]

  • 7. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F, Bramlage P, Paar WD.
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [Abstract] [Full Text] [Related]

  • 8. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [Abstract] [Full Text] [Related]

  • 9. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 10. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 11. [Effect of irbesartan in proteinuric non-diabetic renal disease].
    de Gracia MC, Molina M, Navarro MJ, Garcia Hernández MA.
    Nefrologia; 2005 Dec; 25(5):509-14. PubMed ID: 16392300
    [Abstract] [Full Text] [Related]

  • 12. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E, PRONEDI Study Group.
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [Abstract] [Full Text] [Related]

  • 13. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):851-60. PubMed ID: 11565517
    [Abstract] [Full Text] [Related]

  • 14. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Evans M, Bain SC, Hogan S, Bilous RW, Collaborative Study Group participants.
    Nephrol Dial Transplant; 2012 Jun 20; 27(6):2255-63. PubMed ID: 22172728
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY, Lin FJ, Ou HT, Huang SH, Wang CC.
    Kidney Blood Press Res; 2017 Jun 20; 42(2):358-368. PubMed ID: 28618426
    [Abstract] [Full Text] [Related]

  • 16. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):870-8. PubMed ID: 11565519
    [Abstract] [Full Text] [Related]

  • 17. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.
    Nephrol Dial Transplant; 2002 Jun 20; 17(6):1019-24. PubMed ID: 12032191
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
    Angulo E, Robles NR, Grois J, Barquero A, Pérez Miranda M.
    An Med Interna; 2002 Nov 20; 19(11):571-5. PubMed ID: 12522893
    [Abstract] [Full Text] [Related]

  • 19. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
    Kim HS, Kim H, Lee SH, Kim JH.
    J Clin Pharm Ther; 2020 Dec 20; 45(6):1264-1270. PubMed ID: 32737930
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Dec 20; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.